Tagging staphylococcal enterotoxin B (SEB) with TGFaL3 for breast cancer therapy
- 177 Downloads
Recent research has attempted to direct superantigens towards tumors by means of tumor-targeted superantigen (TTS) strategy. In this study, we explored the antitumor property of TTS by fusing the third loop of transforming growth factor α (TGFαL3) to staphylococcal enterotoxin type B (SEB) and investigated the possibility of the therapeutic application of TGFαL3-SEB as a novel antitumor candidate in mice bearing breast cancer. Treatment was performed through intratumoral and intravenous injection of TGFαL3-SEB. Tumor size/volume, long-term survival, and cytokine secretion were assessed. In addition, the toxicity of each treatment on liver and kidneys was examined. Our results indicated that the relative tumor volume significantly increased in the mice receiving intratumoral TGFaL3-SEB (p < 0.05). Surprisingly, 5 out of the 14 mice were cleared from the tumor thoroughly in 10–25 days after intratumoral administration of TGFaL3-SEB. Quantification of cytokines clearly showed that the mice receiving intratumoral SEB significantly secreted higher interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) compared with the other groups (p < 0.05). The antitumor effect was followed by inhibition of cell proliferation (Ki-67) and micro vascularization (CD31). The highest and lowest levels of tumor necrosis were observed in the intratumoral administration of TGFαL3-SEB (85 %) and PBS (14 %), respectively. Intratumoral injection of TGFαL3-SEB increased the lifespan of the mice so 37.5 % of them could survive for more than 6 months (p < 0.05). Overall, our findings indicated that intratumoral administration of TGFαL3-SEB effectively inhibited the growth of breast tumors through induction of necrosis and suppressing proliferation and angiogenesis without systemic toxicity.
KeywordsBreast cancer Immunotherapy Staphylococcal enterotoxin type B Transforming growth factor α
This study was financially supported by the Pasteur Institute of Iran (Ph.D Grant No. B-8804).
Consent for publication
All of the animal experiments were carried out under a project license issued by the Pasteur Institute of Iran according to the local Animal Experimentation Rules.
Conflicts of interest
- 5.Mohamadabadi MA, Hassan ZM, Zavaran A, Hosseini MG, Noori S, Mahdavi M, et al. Arteether exerts antitumor activity and reduces cd4+ cd25+ foxp3+ t-reg cells. Iran J Immunol. 2013;10:139.Google Scholar
- 6.Soliman H. Immunotherapy strategies in the treatment of breast cancer. Cancer Control 2013;20(1):17–21.Google Scholar
- 9.Li SC, Kabeer MH. Designer immunotherapy specific for cancer. J Cell Sci Ther. 2013;4:e116.Google Scholar
- 13.Terman DS, Serier A, Dauwalder O, Badiou C, Dutour A, Thomas D, Brun V, Bienvenu J, Etienne J, Vandenesch F. Staphylococcal entertotoxins of the enterotoxin gene cluster (egcses) induce nitrous oxide-and cytokine dependent tumor cell apoptosis in a broad panel of human tumor cells. Front Cell Infect Microbiol 2013;13:38.Google Scholar
- 14.Yousefi F, Mousavi SF, Siadat SD, Aslani MM, Amani J, Rad HS, Fooladi AAI. Preparation and in vitro evaluation of antitumor activity of tgfαl3-seb as a ligand-targeted superantigen. Cancer Res treat 2015. doi: 10.1177/1533034614568753.
- 15.Xu M-K, Zhang C-G, Chen Y, Guo W, Cai Y-M, Liu C-X. Research advances on immunopharmacology and cancer therapy of staphylococcal enterotoxins. Asian J Pharmacodyn Pharmacokinet. 2008;8:83–108.Google Scholar
- 18.Wu H-C, Chang D-K, Huang C-T. Targeted-therapy for cancer. J Cancer Mol. 2006;2:57–66.Google Scholar
- 19.Hosseini HM, Fooladi AAI, Soleimanirad J, Nourani MR, Mahdavi M. Exosome/staphylococcal enterotoxin b, an anti tumor compound against pancreatic cancer. J BUON. 2014;19:440–8.Google Scholar
- 22.Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield M. Close similarity of epidermal growth factor receptor and v-erb-b oncogene protein sequences. Nature. 1984 ;307(5951):521–7.Google Scholar
- 26.Connor AE, Baumgartner RN, Baumgartner KB, Pinkston CM, John EM, Torres-Mejía G, et al. Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among hispanic and non-hispanic white women: the breast cancer health disparities study. Int J Mol Epidemiol Genet. 2013;4:235.PubMedPubMedCentralGoogle Scholar
- 37.Xanthopoulos J, Romano A, Majumdar S. Response of mouse breast cancer cells to anastrozole, tamoxifen, and the combination. BioMed Res Int. 2005;2005:10–9.Google Scholar
- 41.Fooladi AAI, Halabian R, Mahdavi M, Amin M, Hosseini HM. Staphylococcal enterotoxin b/texosomes as a candidate for breast cancer immunotherapy. Tumor Biol. 2015;1–10. doi: 10.1007/s13277-015-3877-1.
- 44.Celikoglu F, Celikoglu SI, Goldberg EP. Techniques for intratumoral chemotherapy of lung cancer by bronchoscopic drug delivery. Cancer Ther. 2008;6:545–52.Google Scholar
- 49.Miller F, Miller B, Heppner G. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis. 1982;3:22–31.Google Scholar
- 50.Miller F. Tumor subpopulation interactions in metastasis. Invasion Metastasis. 1982;3:234–42.Google Scholar
- 54.Tong Q, Liu K, Lu X-M, Shu X-G, Wang G-B. Construction and characterization of a novel fusion protein mg7-scfv/seb against gastric cancer. J of Biomed and Biotechnol. 2010. doi: 10.1155/2010/121094.
- 55.Fooladi A, Sattari M, Nourani MR. Synergistic effects between staphylococcal enterotoxin type b and Monophosphoryl lipid A against mouse fibrosarcoma. J BUON. 2010;15:340–7.Google Scholar